News
Alderley Park, Cheshire, U.K – Infex Therapeutics, a leading anti-infectives specialist, is delighted to announce a successful grant award of £850,000 to support its 18 month, £1m COV-X project, titled: “Optimisation o...
Manchester, UK, August 02, 2022: Monument Therapeutics, a stratified medicine company, announced at the British Association for Psychopharmacology conference, positive preclinical results supporting the use of their proprietary non-invasive d...
A device that can help speed the diagnosis of peritonitis in vulnerable kidney and liver failure patients. With results 10,000x faster than current methods, this portable and rapid detection device now means that nurses can carry out an instant le...
The outstanding results being achieved by the Infection Innovation Consortium – iiCON – have been acknowledged today, with £1.7 million of additional funding from Research England confirmed.
Led by Liverpool School of Tropical M...
Manchester, UK, June 13, 2022: Monument Therapeutics, a stratified medicine company, today announced that their first-in-human Phase I study of MT1980, a novel formulation of an on-market anti-inflammatory compound, has commenced. MT1980 has been...